MA49249A - Nouveaux anticorps anti-hsa - Google Patents

Nouveaux anticorps anti-hsa

Info

Publication number
MA49249A
MA49249A MA049249A MA49249A MA49249A MA 49249 A MA49249 A MA 49249A MA 049249 A MA049249 A MA 049249A MA 49249 A MA49249 A MA 49249A MA 49249 A MA49249 A MA 49249A
Authority
MA
Morocco
Prior art keywords
new anti
hsa antibodies
hsa
antibodies
new
Prior art date
Application number
MA049249A
Other languages
English (en)
Inventor
Tessa Bieri
Tea Gunde
Christian Hess
Sebastian Meyer
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA49249A publication Critical patent/MA49249A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049249A 2017-06-05 2018-06-04 Nouveaux anticorps anti-hsa MA49249A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515293P 2017-06-05 2017-06-05
EP17195783 2017-10-10

Publications (1)

Publication Number Publication Date
MA49249A true MA49249A (fr) 2021-04-14

Family

ID=62555062

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049249A MA49249A (fr) 2017-06-05 2018-06-04 Nouveaux anticorps anti-hsa

Country Status (10)

Country Link
US (1) US11365240B2 (fr)
EP (1) EP3634997B8 (fr)
JP (1) JP7130678B2 (fr)
KR (1) KR102754842B1 (fr)
CN (1) CN110709418B (fr)
AU (1) AU2018280679B2 (fr)
CA (1) CA3064160A1 (fr)
ES (1) ES3015094T3 (fr)
IL (1) IL271127B2 (fr)
MA (1) MA49249A (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201911527QA (en) * 2017-06-05 2020-01-30 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
CN113817686B (zh) * 2020-06-18 2023-11-14 上海医药工业研究院 一种杂交瘤细胞株及其分泌的单克隆抗体和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
CN116355092B (zh) * 2023-05-19 2023-07-21 广州明药科技有限公司 抗人血清白蛋白的纳米抗体及其应用
CN118667000A (zh) * 2024-06-28 2024-09-20 杭州旭科生物技术有限公司 抗hsa单克隆抗体及其应用
CN119331089B (zh) * 2024-12-19 2025-04-01 北京索莱宝科技有限公司 抗人白蛋白抗体7g7、抗体组合物及其应用
CN119320449B (zh) * 2024-12-19 2025-04-01 北京索莱宝科技有限公司 抗人白蛋白抗体5h11及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2737241C (fr) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Proteines de fusion d'anticorps multivalentes
EP3656788A3 (fr) * 2009-02-19 2020-07-29 Glaxo Group Limited Variants de liaison anti-albumine sérique améliorés
EP2398825B1 (fr) * 2009-02-19 2017-10-25 Glaxo Group Limited Domaine variable unique anti-albumine serique
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2013068571A1 (fr) 2011-11-11 2013-05-16 Ucb Pharma S.A. Anticorps se liant à l'albumine et leurs fragments de liaison
EP2906596B1 (fr) * 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
IL243311B (en) * 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
SG11201911527QA (en) * 2017-06-05 2020-01-30 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
CN120248120A (zh) * 2017-10-10 2025-07-04 努玛治疗有限公司 靶向pdl1的抗体及其使用方法
AU2018348431B2 (en) * 2017-10-10 2025-10-02 Numab Therapeutics AG Antibodies targeting CD137 and methods of use thereof

Also Published As

Publication number Publication date
CA3064160A1 (fr) 2018-12-13
KR102754842B1 (ko) 2025-01-17
AU2018280679A1 (en) 2019-12-05
AU2018280679B2 (en) 2025-04-24
US20200325214A1 (en) 2020-10-15
EP3634997B8 (fr) 2025-04-02
EP3634997C0 (fr) 2025-02-26
ES3015094T3 (en) 2025-04-29
IL271127B2 (en) 2024-10-01
CN110709418B (zh) 2023-09-26
IL271127A (en) 2020-01-30
EP3634997B1 (fr) 2025-02-26
JP2020522250A (ja) 2020-07-30
US11365240B2 (en) 2022-06-21
KR20200015505A (ko) 2020-02-12
EP3634997A1 (fr) 2020-04-15
IL271127B1 (en) 2024-06-01
CN110709418A (zh) 2020-01-17
JP7130678B2 (ja) 2022-09-05

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
EP3498840A4 (fr) Anticorps anti-lag-3
EP3883970A4 (fr) Anticorps anti-b7-h3
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
EP3423089A4 (fr) Anticorps anti-tigit
MA50352A (fr) Anticorps multispécifiques
MA47268A (fr) Anticorps anti-gpc3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
EP3349787A4 (fr) Anticorps cd47 thérapeutiques
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3596126A4 (fr) Nouveaux anticorps anti-trkb
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap
MA49249A (fr) Nouveaux anticorps anti-hsa
MA49250A (fr) Nouveaux anticorps anti-cd3
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3399992A4 (fr) Anticorps autoréticulants
EP3526251A4 (fr) Anticorps anti-p53
MA51134A (fr) Anticorps anti-alpha-synucléine